Nadia Barghouthi
Endocrinology, Diabetes & Metabolism · Morgantown, WVNPI 1326433798
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,025 of the $1,201 with a category attached, or 85.3%. 13 manufacturers reported payments, led by Medtronic at 35.5% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in WV, where the typical reported total is $1,166.
Across 54 payments — averaging $22.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$427
- Novo Nordisk$181
- Lilly USA, LLC$155
- Abbott$111
- Cequr Corporation$72
- Sanofi-aventis U.S. LLC$69
- plus $186 from 7 others
Across 1 payment — averaging $450.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rhythm Pharmaceuticals, Inc.$450
What the payments were for
- Food & beverage$1,02585%
- Education$12610%
- Other$504%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 15 | $427 |
| Novo Nordisk | 11 | $181 |
| Lilly USA, LLC | 9 | $155 |
| Abbott | 4 | $111 |
| Cequr Corporation | 2 | $72 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Boehringer Ingelheim | 2 | $56 |
| Ascendis Pharma Endocrinology Inc | 2 | $49 |
| Insulet Corporation | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Pfizer | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
How this compares
$1,201 in reported general payments places this provider in the 50th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 150 | $214,049 |
| OzempicSemaglutide | 129 | $205,564 |
| TrulicityDulaglutide | 93 | $153,227 |
| JardianceEmpagliflozin | 80 | $94,249 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $87,584 |
| ForteoTeriparatide | 15 | $58,539 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $30,321 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $26,794 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $23,810 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $23,228 |
| FarxigaDapagliflozin Propanediol | 33 | $22,714 |
| InvokanaCanagliflozin | 14 | $20,188 |
| Novolog FlexpenInsulin Aspart | 30 | $17,565 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $16,256 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $9,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo | $155 | $425,815258 claims |
| Novo NordiskOzempic | $181 | $205,564129 claims |
| Boehringer IngelheimJardiance | $56 | $94,24980 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Morgantown
- Jessica PeriniMorgantown$10K
- Jennifer TurnerMorgantown$6K
- Adnan HaiderMorgantown$3K
- Jennifer GiordanoMorgantown$2K
- Apoorva IyerMorgantown$1K
- Jeffrey Zen-Ji RicoMorgantown$1K
- Tariq LatifMorgantown$844
- Mehjabeen SadiqMorgantown$684
- Sarah FatimaMorgantown$292
- Ann-Marie BusickMorgantown$227
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.